Phanes Therapeutics' PT217 Receives Orphan Drug Designation for Neuroendocrine Carcinoma From the FDA
Phanes Therapeutics的PT217获得FDA颁发的神经内分泌癌症孤儿药物认证
Phanes Therapeutics' PT217 Receives Orphan Drug Designation for Neuroendocrine Carcinoma From the FDA
Phanes Therapeutics的PT217获得FDA颁发的神经内分泌癌症孤儿药物认证
使用浏览器的分享功能,分享给你的好友吧